skip to Main Content

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers.

© 2025 AccentBio. All Rights Reserved.
Site designed by Grid24 a division of Grid24 Ltd.

Back To Top